| Graphite Bio is a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases. Co.'s primary product candidate GPH101 is an approach with the potential to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression. Co.'s pipeline also includes GPH102 for beta-thalassemia and GPH201 for X-linked severe combined immunodeficiency syndrome; GPH301 for Gaucher disease and an early-stage research program for alpha-1 antitrypsin deficiency; and various undisclosed programs in both hematopoietic stem cells and other cell types. The GRPH average annual return since 2021 is shown above.
The Average Annual Return on the GRPH average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GRPH average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GRPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).